Pharma-Size That: Galapagos Expands RA Drug Development With Blockbuster J&J Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Alliance valued at over €1 billion includes potential landmark €60 million license on Galapagos' lead internal rheumatoid arthritis candidate GT418.
You may also be interested in...
Galapagos Coasts Through Recession On Deals With Merck And Other Big Pharmas
Low-commitment, option-based alliances with Big Pharma bolster Belgian biotech’s own pipeline.
Galapagos Coasts Through Recession On Deals With Merck And Other Big Pharmas
Low-commitment, option-based alliances with Big Pharma bolster Belgian biotech’s own pipeline.
Galapagos Hits Two Partnership Milestones
Step in osteoporosis deal earns firm €1 million from Lilly.